JP2022546597A5 - - Google Patents

Info

Publication number
JP2022546597A5
JP2022546597A5 JP2022514708A JP2022514708A JP2022546597A5 JP 2022546597 A5 JP2022546597 A5 JP 2022546597A5 JP 2022514708 A JP2022514708 A JP 2022514708A JP 2022514708 A JP2022514708 A JP 2022514708A JP 2022546597 A5 JP2022546597 A5 JP 2022546597A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
item
itr
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022514708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546597A (ja
JP7700101B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049266 external-priority patent/WO2021046265A1/en
Publication of JP2022546597A publication Critical patent/JP2022546597A/ja
Publication of JP2022546597A5 publication Critical patent/JP2022546597A5/ja
Application granted granted Critical
Publication of JP7700101B2 publication Critical patent/JP7700101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514708A 2019-09-06 2020-09-03 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 Active JP7700101B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962896980P 2019-09-06 2019-09-06
US62/896,980 2019-09-06
US201962910720P 2019-10-04 2019-10-04
US62/910,720 2019-10-04
US201962940104P 2019-11-25 2019-11-25
US62/940,104 2019-11-25
PCT/US2020/049266 WO2021046265A1 (en) 2019-09-06 2020-09-03 Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022546597A JP2022546597A (ja) 2022-11-04
JP2022546597A5 true JP2022546597A5 (enExample) 2023-09-11
JP7700101B2 JP7700101B2 (ja) 2025-06-30

Family

ID=74853052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514708A Active JP7700101B2 (ja) 2019-09-06 2020-09-03 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法

Country Status (8)

Country Link
US (1) US20220280427A1 (enExample)
EP (1) EP4025196A4 (enExample)
JP (1) JP7700101B2 (enExample)
CN (1) CN114929205B (enExample)
AU (1) AU2020342668B2 (enExample)
CA (1) CA3150452A1 (enExample)
IL (1) IL291038A (enExample)
WO (1) WO2021046265A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4035686A4 (en) * 2019-09-26 2023-11-01 NOF Corporation FREEZE DRIED COMPOSITION OF LIPID NANOPARTICLES
JP7746280B2 (ja) 2020-03-27 2025-09-30 ジェネレーション バイオ カンパニー 新規脂質及びそれらのナノ粒子組成物
IL298241A (en) * 2020-05-18 2023-01-01 Generation Bio Co New lipids and their nanoparticle preparations
AU2021307952A1 (en) * 2020-07-17 2023-03-02 Generation Bio Co. Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Dna分子の組成物、その作製方法、及びその使用方法
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CA3221454A1 (en) * 2021-06-07 2022-12-15 Michelle LEBLANC Apoe and apob modified lipid nanoparticle compositions and uses thereof
AU2022291742A1 (en) * 2021-06-14 2023-12-21 Generation Bio Co. Cationic lipids and compositions thereof
KR20240038705A (ko) * 2021-06-22 2024-03-25 인텔리아 테라퓨틱스, 인크. 간 유전자의 생체 내 편집 방법
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
US12251471B2 (en) * 2021-07-26 2025-03-18 Oregon State University Inhalable therapeutics
CA3234321A1 (en) * 2021-09-30 2023-04-06 Nof Corporation Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells
CN114432502B (zh) * 2021-12-31 2023-02-03 中山大学附属第八医院(深圳福田) 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用
US20260115316A1 (en) * 2022-03-28 2026-04-30 Nof Corporation Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same
WO2023190175A1 (ja) * 2022-03-28 2023-10-05 日油株式会社 末梢血単核細胞へ核酸を送達するための脂質ナノ粒子およびこれを用いて末梢血単核細胞へ核酸を送達する方法
CA3256897A1 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for the administration of nucleic acids and their methods of use
WO2024112943A1 (en) * 2022-11-22 2024-05-30 University Of Maryland, Baltimore Activated nanotherapy for sickle cell disease
WO2024140893A1 (zh) 2022-12-29 2024-07-04 辽宁键凯科技有限公司 一种类固醇-阳离子脂质化合物及其应用
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025188836A1 (en) * 2024-03-05 2025-09-12 Saliogen Therapeutics, Inc. Compositions and methods of using gene coding for treating ocular disease
WO2025213135A1 (en) * 2024-04-04 2025-10-09 The Brigham And Women's Hospital, Inc. Lipid nanoparticles for the treatment of vascular diseases
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US7201898B2 (en) 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
WO2004078941A2 (en) 2003-03-06 2004-09-16 Oligo Engine, Inc. Modulation of gene expression using dna-rna hybrids
US20050148531A1 (en) 2003-05-15 2005-07-07 Todd Hauser Modulation of gene expression using DNA-DNA hybrids
EP1664316B1 (en) 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
CA2689042A1 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US8883211B2 (en) 2008-07-10 2014-11-11 Serina Therapeutics, Inc. Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012024526A2 (en) 2010-08-20 2012-02-23 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
CA2809858C (en) 2010-09-20 2019-11-12 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
ES2795110T3 (es) 2011-06-08 2020-11-20 Translate Bio Inc Lípidos escindibles
EP3485875A1 (en) 2011-11-04 2019-05-22 Nitto Denko Corporation Single use system for sterelily producing lipid-nucleic acid particles
WO2013073480A1 (ja) 2011-11-18 2013-05-23 日油株式会社 細胞内動態を改善したカチオン性脂質
AU2013237874B2 (en) * 2012-03-29 2018-01-18 Translate Bio, Inc. Lipid-derived neutral nanoparticles
AU2014348212C1 (en) 2013-11-18 2018-11-29 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
WO2016079197A1 (en) * 2014-11-18 2016-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Delivery enhancers for conjugated sirna and lipid nanoparticles
CA2975371C (en) * 2015-01-30 2024-02-13 Nof Corporation Cationic lipid for nucleic acid delivery
PT3313829T (pt) 2015-06-29 2024-07-08 Acuitas Therapeutics Inc Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
HRP20230209T1 (hr) 2015-10-28 2023-04-14 Acuitas Therapeutics Inc. Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3315125A1 (en) * 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
WO2018237369A2 (en) * 2017-06-23 2018-12-27 Vical Incorporated Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection
CA3075168A1 (en) * 2017-09-08 2019-03-14 Generation Bio Co. Modified closed-ended dna (cedna)
KR102696307B1 (ko) * 2017-09-08 2024-08-16 제너레이션 바이오 컴퍼니 비-바이러스성 캡시드-비함유 dna 벡터의 지질 나노입자 제형
KR20200120649A (ko) * 2018-02-14 2020-10-21 제너레이션 바이오 컴퍼니 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도
CN111902397B (zh) * 2018-03-27 2024-04-12 日油株式会社 改进了细胞内动力学的阳离子脂质

Similar Documents

Publication Publication Date Title
JP2022546597A5 (enExample)
JP2023502576A5 (enExample)
JP2023518985A5 (enExample)
JP2023534043A5 (enExample)
US12252470B2 (en) Lipids and nanoparticle compositions thereof
JP2024517644A5 (enExample)
AU2020342668B2 (en) Lipid nanoparticle compositions comprising closed-ended DNA and cleavable lipids and methods of use thereof
JP2024522692A5 (enExample)
US20230320993A1 (en) Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof
JP2023527747A5 (enExample)
US20240293574A1 (en) Cationic lipids and compositions thereof
US20250249123A1 (en) Lipids and compositions thereof
JP2024520756A5 (enExample)
US20230181764A1 (en) Novel lipids and nanoparticle compositions thereof
JP2024529343A5 (enExample)
RU2023129760A (ru) Катионные липиды и их композиции
RU2023135629A (ru) Катионные липиды и их композиции